Fortress Biotech’s Majority-Controlled Subsidiary, Journey Medical Corporation, Receives FDA Approval for Emrosi™ for Rosacea Treatment
Fortress Biotech, Inc. (NASDAQ: FBIO) announced through its majority-controlled subsidiary, Journey Medical Corporation, that the U.S. Food and Drug Administration (FDA) has approved Emrosi™ ...
What's Going On With Journey Medical Stock Today?
Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...
US FDA approves Journey Medical's drug for long-term skin condition
The U.S. Food and Drug Administration has approved Journey Medical's drug for the treatment of a long-term skin condition ...
GlobalData on MSN14h
FDA approves Journey Medical’s rosacea treatment Emrosi
The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline ...
Yahoo Finance12d
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
SCOTTSDALE, Ariz., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling ...
Stockhouse11d
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
Oct. 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and ...
Business Insider12d
Journey Medical announces presentation of DFD-29 data
Journey Medical (DERM) presented data assessing the dermal and systemic pharmacokinetics of oral DFD-29 versus oral Doxycycline 40 mg capsules in healthy subjects at the 44th Fall Clinical ...
Investing6d
Journey Medical Corp (DERM)
In a recent transaction, Claude Maraoui, President and CEO of Journey Medical Corp (NASDAQ:DERM), bolstered his stake in the company by purchasing $34,790 worth of shares. The... In a recent ...